Source: International Congress 2016 – IPF pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mareike Lehmann (München, Germany), Mareike Lehmann, Lara Buhl, Darcy Wagner, Jürgen Behr, Michael Lindner, Melanie Königshoff. LATE-BREAKING ABSTRACT: Anti-fibrotic effects of nintedanib and pirfenidone in 2D versus 3D lung cultures. Eur Respir J 2016; 48: Suppl. 60, 478

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Abnormal proliferation and differentiation of c-kit+ lung stem cells in pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016